GSK Vaccines Deal History & Licensing Activity
GSK Vaccines is a large pharma headquartered in UK. Over the past three years, GSK Vaccines has been involved in 5 licensing and acquisition transactions, with a primary focus on Oligonucleotides (3 deals).
Deals (12mo)
2
Active Trials
30
Top Modality
Oligonucleotides
Focus Area
Option Deals
GSK Vaccines Recent Deal Activity
Licensing, acquisition, and partnership transactions involving GSK Vaccines in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| siRNA obesity program | GSK | Oligonucleotides | Preclinical | acquisition | May 2026 |
| HRS-9821 | GSK | Small Molecules | Unknown | option | Jun 2025 |
GSK Vaccines Pipeline Focus
Therapeutic areas and modalities where GSK Vaccines is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
GSK Vaccines Strategic Signals
Key indicators of GSK Vaccines's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches GSK Vaccines's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Option Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About GSK Vaccines Licensing & Deal Activity
GSK Vaccines is a large pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, GSK Vaccines ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for GSK Vaccines include Option Deals (3 deals and trials), Mega Deals (2 deals and trials), Codev Deals (1 deal and trial), and Immunology (1 deal and trial). In terms of modality, GSK Vaccines has shown particular interest in oligonucleotides, small molecules, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for GSK Vaccines and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against GSK Vaccines's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.